{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T14:28:00Z","timestamp":1777300080693,"version":"3.51.4"},"reference-count":24,"publisher":"California Digital Library (CDL)","issue":"1","license":[{"start":{"date-parts":[[2019,1,4]],"date-time":"2019-01-04T00:00:00Z","timestamp":1546560000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Neuroleptic malignant syndrome (NMS) is a rare but potentially fatal complication resulting from neuroleptic drug therapy. Presentation of NMS can vary, and diagnosis relies primarily upon medical history and symptomatology. Due to the potential delay in diagnosis, emergency physicians should remain vigilant in recognizing the symptoms of NMS and be prepared to initiate immediate treatment following diagnosis. Dantrolene, which has been used for spasticity and malignant hyperthermia, has been reported as a potential treatment for NMS and led to off-label use for NMS. We report two cases of NMS induced by antipsychotic monotherapy for which dantrolene was administered.<\/jats:p>","DOI":"10.5811\/cpcem.2018.11.39667","type":"journal-article","created":{"date-parts":[[2019,2,25]],"date-time":"2019-02-25T15:22:07Z","timestamp":1551108127000},"page":"16-23","source":"Crossref","is-referenced-by-count":9,"title":["Emergent Treatment of Neuroleptic Malignant Syndrome Induced by Antipsychotic Monotherapy Using Dantrolene"],"prefix":"10.5811","volume":"3","author":[{"given":"Vivian","family":"Ngo","sequence":"first","affiliation":[{"name":"Arrowhead Regional Medical Center, Department of Family Medicine, Colton, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo","family":"Guerrero","sequence":"additional","affiliation":[{"name":"Arrowhead Regional Medical Center, Department of Emergency Medicine, Colton, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Lanum","sequence":"additional","affiliation":[{"name":"Arrowhead Regional Medical Center, Department of Family Medicine, Colton, California; California University of Sciences and Medicine, Department of Emergency Medicine, Colton, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Burgett-Moreno","sequence":"additional","affiliation":[{"name":"Arrowhead Regional Medical Center, Department of Emergency Medicine, Colton, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"Fenati","sequence":"additional","affiliation":[{"name":"Arrowhead Regional Medical Center, Department of Emergency Medicine, Colton, California; California University of Sciences and Medicine, Department of Emergency Medicine, Colton, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Barr","sequence":"additional","affiliation":[{"name":"Arrowhead Regional Medical Center, Department of Anesthesia, Colton, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Neeki","sequence":"additional","affiliation":[{"name":"Arrowhead Regional Medical Center, Department of Emergency Medicine, Colton, California; California University of Sciences and Medicine, Department of Emergency Medicine, Colton, California"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"29705","published-online":{"date-parts":[[2019,1,4]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Al Danaf J, Madara J, Dietsche C. Neuroleptic malignant syndrome: a case aimed at raising clinical awareness. Case Rep Med. 2015;2015:769576.","DOI":"10.1155\/2015\/769576"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Berman BD. Neuroleptic malignant syndrome: a review for neurohospitalists. Neurohospitalist. 2011;1(1):41-7.","DOI":"10.1177\/1941875210386491"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Strawn JR, Keck PE Jr, Caroff SN, et al. Neuroleptic malignant syndrome. Am J Psychiatry. 2007;164(6):870-6.","DOI":"10.1176\/ajp.2007.164.6.870"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry. 1985;142(10):1137-45.","DOI":"10.1176\/ajp.142.10.1137"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders (5th ed.). Arlington, VA: American Psychiatric Association Publishing.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Caroff SN and Mann SC. Neuroleptic malignant syndrome. Med Clin North Am. 1993;77(1):185-202.","DOI":"10.1016\/S0025-7125(16)30278-4"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Leenhardt F, Perier D, Pinzani V, et al. Pharmacist intervention to detect drug adverse events on admission to the emergency department: Two case reports of neuroleptic malignant syndrome. J Clin Pharm Ther. 2017;42(4):502-5.","DOI":"10.1111\/jcpt.12531"},{"key":"ref7","unstructured":"Wijdicks EF. Neuroleptic malignant syndrome. Available at: https:\/\/www.uptodate.com\/contents\/neuroleptic-malignant-syndrome. Accessed March 10, 2017."},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Grossman RA, Hamilton RW, Morse BM, et al. Nontraumatic rhabdomyolysis and acute renal failure. N Engl J Med. 1974;291(16):807-11.","DOI":"10.1056\/NEJM197410172911601"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Reulbach U, D\u00fctsch C, Biermann T, et al. Managing an effective treatment for neuroleptic malignant syndrome. Crit Care. 2007;11(1):R4.","DOI":"10.1186\/cc5148"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Drews JD, Christopher A, Evans DC. Neuroleptic malignant syndrome in the trauma intensive care unit: Diagnosis and management of a rare disease in a challenging population. Int J Crit Illn Inj Sci. 2017;7(2):119-21.","DOI":"10.4103\/ijciis.ijciis_100_16"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Saha PK, Chakraborty A, Layek AK, et al. Olanzapine-induced neuroleptic malignant syndrome. Indian J Psychol Med. 2017;39(3):364-5.","DOI":"10.4103\/0253-7176.207320"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Ahmad A, Harrison CA, Davies HG. Two unusual complications of neuroleptic malignant syndrome. Indian J Crit Care Med. 2013;17(2):116-8.","DOI":"10.4103\/0972-5229.114823"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Kuchibatla SS, Cheema SA, Chakravarthy KS, et al. A case report of neuroleptic malignant syndrome. BMJ Case Rep. 2009;2009:bcr0720080429.","DOI":"10.1136\/bcr.07.2008.0429"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Rajamani B, Kumar Y, Rahman SM. Neuroleptic malignant syndrome. J Family Med Prim Care. 2016;5(1):178-80.","DOI":"10.4103\/2249-4863.184660"},{"key":"ref15","unstructured":"Chandran GJ, Mikler JR, Keegan DL. Neuroleptic malignant syndrome: case report and discussion. CMAJ. 2003;169(5):439-42."},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"\u0160agud M, Vuksan-Cusa B, Bo\u017eina N, et al. Olanzapine long-acting injections after neuroleptic malignant syndrome: two case reports. J Clin Psychopharmacol. 2016;36(6):733-5.","DOI":"10.1097\/jcp.0000000000000568"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Ambulkar RP, Patil VP, Moiyadi AV. Neuroleptic malignant syndrome: a diagnostic challenge. J Anaesthesiol Clin Pharmacol. 2012;28(4):517-9.","DOI":"10.4103\/0970-9185.101946"},{"key":"ref18","unstructured":"Bottoni TN. Neuroleptic malignant syndrome: a brief review. Hosp Physician. 2002;38(3):58-63."},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Yamawaki S, Yanagawa K, Morio M, et al. Possible central effect of dantrolene sodium in neuroleptic malignant syndrome. J Clin Psychopharmacol. 1986;6(6):378-9.","DOI":"10.1097\/00004714-198612000-00020"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Modi S, Dharaiya D, Schultz L, et al. Neuroleptic malignant syndrome: complications, outcomes, and mortality. Neurocrit Care. 2016;24(1):97-103.","DOI":"10.1007\/s12028-015-0162-5"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Muehlschlegel S and Sims JR. Dantrolene: mechanisms of neuroprotection and possible clinical applications in the neurointensive care unit. Neurocrit Care. 2009;10(1):103-15.","DOI":"10.1007\/s12028-008-9133-4"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Oyamada T, Hayashi T, Kagaya A, et al. Effect of dantrolene on K+-and caffeine-induced dopamine release in rat striatum assessed by in vivo microdialysis. Neurochem Int. 1998;32(2):171-6.","DOI":"10.1016\/s0197-0186(97)00068-5"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Brvar M and Bunc M. Video of dantrolene effectiveness on neuroleptic malignant syndrome-associated muscular rigidity and tremor. Crit Care. 2007;11(3):415.","DOI":"10.1186\/cc5907"}],"container-title":["Clinical Practice and Cases in Emergency Medicine"],"original-title":[],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T13:18:12Z","timestamp":1574083092000},"score":1,"resource":{"primary":{"URL":"https:\/\/escholarship.org\/uc\/item\/74v0t38z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,4]]},"references-count":24,"issue-title":["Clinical Practice and Cases in Emergency Medicine"],"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,2,1]]}},"URL":"https:\/\/doi.org\/10.5811\/cpcem.2018.11.39667","relation":{},"ISSN":["2474-252X","2474-252X"],"issn-type":[{"value":"2474-252X","type":"electronic"},{"value":"2474-252X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1,4]]}}}